Autoimmune Disorders Associated with Gain of Function of the Intracellular Sensor MDA5

Immunity

Volumn 40, Issue 2, 2014, Pages 199-212

  Funabiki, Masahide ^a   Kato, Hiroki ^a,b   Miyachi, Yoshiki ^a   Toki, Hideaki ^c   Motegi, Hiromi ^c   Inoue, Maki ^c   Minowa, Osamu ^c   Yoshida, Aiko ^a   Deguchi, Katashi ^a   Sato, Hiroshi ^d   Ito, Sadayoshi ^e   Shiroishi, Toshihiko ^f   Takeyasu, Kunio ^a   Noda, Tetsuo ^c,g   Fujita, Takashi ^a  

^a KYOTO UNIVERSITY   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^c RIKEN   (Japan)

^d TOHOKU UNIVERSITY   (Japan)

^e TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^f NATIONAL INSTITUTE OF GENETICS   (Japan)

^g CANCER INSTITUTE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; AUTOIMMUNE DISEASES; CELLS, CULTURED; DEAD-BOX RNA HELICASES; DISEASE MODELS, ANIMAL; INTERFERON-ALPHA; MICE; MUTATION;

ADENOSINE TRIPHOSPHATASE; AMINO ACID; BETA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERFERON RECEPTOR; INTERLEUKIN 6; LIGAND; PROTEIN; PROTEIN MDA5; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CLINICAL FEATURE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; EXON; FEMALE; GAIN OF FUNCTION MUTATION; INFLAMMATION; INNATE IMMUNITY; LUPUS LIKE SYNDROME; MALE; MOUSE; MOUSE MUTANT; MUTAGENESIS; NEPHRITIS; NONHUMAN; PHENOTYPE; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; UPREGULATION;

EID: 84894028950     PISSN: 10747613     EISSN: 10974180     Source Type: Journal    
DOI: 10.1016/j.immuni.2013.12.014     Document Type: Article

References (46)

1. Bamming D., Horvath C.M. Regulation of signal transduction by enzymatically inactive antiviral RNA helicase proteins MDA5, RIG-I, and LGP2. J.Biol. Chem. 2009, 284:9700-9712.
2. Banchereau J., Pascual V. Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity 2006, 25:383-392.
3. Beutler B. Microbe sensing, positive feedback loops, and the pathogenesis of inflammatory diseases. Immunol. Rev. 2009, 227:248-263.
4. Bihl T., Vassina E., Boettger M.K., Goldbach-Mansky R., Seitz M., Villiger P.M., Simon H.U. The T348M mutated form of cryopyrin is associated with defective lipopolysaccharide-induced interleukin 10 production in CINCA syndrome. Ann. Rheum. Dis. 2005, 64:1380-1381.
5. Christensen S.R., Shupe J., Nickerson K., Kashgarian M., Flavell R.A., Shlomchik M.J. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity 2006, 25:417-428.
6. Crampton S.P., Deane J.A., Feigenbaum L., Bolland S. Ifih1 gene dose effect reveals MDA5-mediated chronic type I IFN gene signature, viral resistance, and accelerated autoimmunity. J.Immunol. 2012, 188:1451-1459.
7. Dinarello C.A. Unraveling the NALP-3/IL-1beta inflammasome: a big lesson from a small mutation. Immunity 2004, 20:243-244.
8. Elinav E., Strowig T., Henao-Mejia J., Flavell R.A. Regulation of the antimicrobial response by NLR proteins. Immunity 2011, 34:665-679.
9. Gall A., Treuting P., Elkon K.B., Loo Y.M., Gale M., Barber G.N., Stetson D.B. Autoimmunity initiates in nonhematopoietic cells and progresses via lymphocytes in an interferon-dependent autoimmune disease. Immunity 2012, 36:120-131.
10. Gateva V., Sandling J.K., Hom G., Taylor K.E., Chung S.A., Sun X., Ortmann W., Kosoy R., Ferreira R.C., Nordmark G., et al. A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus. Nat. Genet. 2009, 41:1228-1233.
11. Hoffman H.M., Mueller J.L., Broide D.H., Wanderer A.A., Kolodner R.D. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat. Genet. 2001, 29:301-305.
12. Hornung V., Ellegast J., Kim S., Brzózka K., Jung A., Kato H., Poeck H., Akira S., Conzelmann K.K., Schlee M., et al. 5'-Triphosphate RNA is the ligand for RIG-I. Science 2006, 314:994-997.
13. Hugot J.P., Chamaillard M., Zouali H., Lesage S., Cézard J.P., Belaiche J., Almer S., Tysk C., O'Morain C.A., Gassull M., et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001, 411:599-603.
14. Imler J.L., Hoffmann J.A. Toll receptors in innate immunity. Trends Cell Biol. 2001, 11:304-311.
15. Kageyama M., Takahasi K., Narita R., Hirai R., Yoneyama M., Kato H., Fujita T. 55 Amino acid linker between helicase and carboxyl terminal domains of RIG-I functions as a critical repression domain and determines inter-domain conformation. Biochem. Biophys. Res. Commun. 2011, 415:75-81.
16. Kato H., Sato S., Yoneyama M., Yamamoto M., Uematsu S., Matsui K., Tsujimura T., Takeda K., Fujita T., Takeuchi O., Akira S. Cell type-specific involvement of RIG-I in antiviral response. Immunity 2005, 23:19-28.
17. Kato H., Takeuchi O., Sato S., Yoneyama M., Yamamoto M., Matsui K., Uematsu S., Jung A., Kawai T., Ishii K.J., et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 2006, 441:101-105.
18. Kato H., Takeuchi O., Mikamo-Satoh E., Hirai R., Kawai T., Matsushita K., Hiiragi A., Dermody T.S., Fujita T., Akira S. Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid-inducible gene-I and melanoma differentiation-associated gene 5. J.Exp. Med. 2008, 205:1601-1610.
19. Kawai T., Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 2011, 34:637-650.
20. Kawai T., Takahashi K., Sato S., Coban C., Kumar H., Kato H., Ishii K.J., Takeuchi O., Akira S. IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction. Nat. Immunol. 2005, 6:981-988.
21. Kowalinski E., Lunardi T., McCarthy A.A., Louber J., Brunel J., Grigorov B., Gerlier D., Cusack S. Structural basis for the activation of innate immune pattern-recognition receptor RIG-I by viral RNA. Cell 2011, 147:423-435.
22. Liu Z., Davidson A. Taming lupus-a new understanding of pathogenesis is leading to clinical advances. Nat. Med. 2012, 18:871-882.
23. Meylan E., Curran J., Hofmann K., Moradpour D., Binder M., Bartenschlager R., Tschopp J. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 2005, 437:1167-1172.
24. Nakashima R., Imura Y., Kobayashi S., Yukawa N., Yoshifuji H., Nojima T., Kawabata D., Ohmura K., Usui T., Fujii T., et al. The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatology (Oxford) 2010, 49:433-440.
25. Nejentsev S., Walker N., Riches D., Egholm M., Todd J.A. Rare variants of IFIH1, a gene implicated in antiviral responses, protect against type 1 diabetes. Science 2009, 324:387-389.
26. Ogura Y., Bonen D.K., Inohara N., Nicolae D.L., Chen F.F., Ramos R., Britton H., Moran T., Karaliuskas R., Duerr R.H., et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001, 411:603-606.
27. Pichlmair A., Schulz O., Tan C.P., Näslund T.I., Liljeström P., Weber F., Reis e Sousa C. RIG-I-mediated antiviral responses to single-stranded RNA bearing 5'-phosphates. Science 2006, 314:997-1001.
28. Pisitkun P., Deane J.A., Difilippantonio M.J., Tarasenko T., Satterthwaite A.B., Bolland S. Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication. Science 2006, 312:1669-1672.
29. Robinson T., Kariuki S.N., Franek B.S., Kumabe M., Kumar A.A., Badaracco M., Mikolaitis R.A., Guerrero G., Utset T.O., Drevlow B.E., et al. Autoimmune disease risk variant of IFIH1 is associated with increased sensitivity to IFN-α and serologic autoimmunity in lupus patients. J.Immunol. 2011, 187:1298-1303.
30. Satoh T., Kato H., Kumagai Y., Yoneyama M., Sato S., Matsushita K., Tsujimura T., Fujita T., Akira S., Takeuchi O. LGP2 is a positive regulator of RIG-I- and MDA5-mediated antiviral responses. Proc. Natl. Acad. Sci. USA 2010, 107:1512-1517.
31. Schlee M., Roth A., Hornung V., Hagmann C.A., Wimmenauer V., Barchet W., Coch C., Janke M., Mihailovic A., Wardle G., et al. Recognition of 5' triphosphate by RIG-I helicase requires short blunt double-stranded RNA as contained in panhandle of negative-strand virus. Immunity 2009, 31:25-34.
32. Seth R.B., Sun L., Ea C.K., Chen Z.J. Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF 3. Cell 2005, 122:669-682.
33. Shigemoto T., Kageyama M., Hirai R., Zheng J., Yoneyama M., Fujita T. Identification of loss of function mutations in human genes encoding RIG-I and MDA5: implications for resistance to type I diabetes. J.Biol. Chem. 2009, 284:13348-13354.
34. Stetson D.B., Ko J.S., Heidmann T., Medzhitov R. Trex1 prevents cell-intrinsic initiation of autoimmunity. Cell 2008, 134:587-598.
35. Sumpter R., Loo Y.M., Foy E., Li K., Yoneyama M., Fujita T., Lemon S.M., Gale M. Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I. J.Virol. 2005, 79:2689-2699.
36. Sun L., Wu J., Du F., Chen X., Chen Z.J. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science 2013, 339:786-791.
37. Takahasi K., Yoneyama M., Nishihori T., Hirai R., Kumeta H., Narita R., Gale M., Inagaki F., Fujita T. Nonself RNA-sensing mechanism of RIG-I helicase and activation of antiviral immune responses. Mol. Cell 2008, 29:428-440.
38. Toki H., Inoue M., Motegi H., Minowa O., Kanda H., Yamamoto N., Ikeda A., Karashima Y., Matsui J., Kaneda H., et al. Novel mouse model for Gardner syndrome generated by a large-scale N-ethyl-N-nitrosourea mutagenesis program. Cancer Sci. 2013, 104:937-944.
39. Trinchieri G. Type I interferon: friend or foe?. J.Exp. Med. 2010, 207:2053-2063.
40. Unterholzner L., Keating S.E., Baran M., Horan K.A., Jensen S.B., Sharma S., Sirois C.M., Jin T., Latz E., Xiao T.S., et al. IFI16 is an innate immune sensor for intracellular DNA. Nat. Immunol. 2010, 11:997-1004.
41. van Heel D.A., Ghosh S., Butler M., Hunt K.A., Lundberg A.M., Ahmad T., McGovern D.P., Onnie C., Negoro K., Goldthorpe S., et al. Muramyl dipeptide and toll-like receptor sensitivity in NOD2-associated Crohn's disease. Lancet 2005, 365:1794-1796.
42. Wu B., Peisley A., Richards C., Yao H., Zeng X., Lin C., Chu F., Walz T., Hur S. Structural basis for dsRNA recognition, filament formation, and antiviral signal activation by MDA5. Cell 2013, 152:276-289.
43. Xu L.G., Wang Y.Y., Han K.J., Li L.Y., Zhai Z., Shu H.B. VISA is an adapter protein required for virus-triggered IFN-beta signaling. Mol. Cell 2005, 19:727-740.
44. Yoneyama M., Fujita T. RNA recognition and signal transduction by RIG-I-like receptors. Immunol. Rev. 2009, 227:54-65.
45. Yoshida H., Okabe Y., Kawane K., Fukuyama H., Nagata S. Lethal anemia caused by interferon-beta produced in mouse embryos carrying undigested DNA. Nat. Immunol. 2005, 6:49-56.
46. Zhang Z., Yuan B., Bao M., Lu N., Kim T., Liu Y.J. The helicase DDX41 senses intracellular DNA mediated by the adaptor STING in dendritic cells. Nat. Immunol. 2011, 12:959-965.